| Primary |
| Multiple Myeloma |
48.6% |
| Drug Use For Unknown Indication |
15.1% |
| Plasma Cell Myeloma |
6.8% |
| Product Used For Unknown Indication |
6.1% |
| Prophylaxis |
5.9% |
| Hypertension |
3.5% |
| Thrombosis Prophylaxis |
3.3% |
| Constipation |
2.3% |
| Pain |
2.1% |
| Myelodysplastic Syndrome |
0.9% |
| Back Pain |
0.6% |
| Diabetes Mellitus |
0.6% |
| Nausea |
0.6% |
| Infection Prophylaxis |
0.6% |
| Atrial Fibrillation |
0.5% |
| Myelofibrosis |
0.5% |
| Medulloblastoma |
0.5% |
| Constipation Prophylaxis |
0.5% |
| Amyloidosis |
0.5% |
| Hypothyroidism |
0.5% |
|
| Multiple Myeloma |
9.4% |
| Sepsis |
8.4% |
| Pneumonia |
7.0% |
| Pulmonary Embolism |
6.4% |
| Thrombocytopenia |
6.2% |
| Renal Failure |
6.0% |
| Disease Progression |
5.6% |
| Acute Myeloid Leukaemia |
5.0% |
| Respiratory Failure |
5.0% |
| Septic Shock |
4.6% |
| Neuropathy Peripheral |
4.2% |
| General Physical Health Deterioration |
4.0% |
| Rash |
4.0% |
| Death |
3.8% |
| Syncope |
3.8% |
| Cardiac Disorder |
3.6% |
| Pyrexia |
3.4% |
| Somnolence |
3.4% |
| Myelodysplastic Syndrome |
3.2% |
| Urinary Tract Infection |
3.0% |
|
| Secondary |
| Multiple Myeloma |
55.2% |
| Plasma Cell Myeloma |
9.0% |
| Product Used For Unknown Indication |
6.8% |
| Drug Use For Unknown Indication |
6.5% |
| Prophylaxis |
4.9% |
| Thrombosis Prophylaxis |
3.3% |
| Hypertension |
2.6% |
| Constipation |
1.5% |
| Pain |
1.5% |
| Infection Prophylaxis |
1.3% |
| Juvenile Arthritis |
1.1% |
| Myelodysplastic Syndrome |
1.0% |
| Mantle Cell Lymphoma |
0.9% |
| Nausea |
0.8% |
| Back Pain |
0.7% |
| Benign Prostatic Hyperplasia |
0.6% |
| Bone Pain |
0.6% |
| Glioblastoma Multiforme |
0.6% |
| Atrial Fibrillation |
0.5% |
| Immunosuppression |
0.5% |
|
| Death |
15.4% |
| Neuropathy Peripheral |
7.5% |
| Pneumonia |
7.5% |
| Pulmonary Embolism |
7.1% |
| Thrombocytopenia |
5.7% |
| Sepsis |
5.5% |
| Gastrointestinal Inflammation |
5.4% |
| Myelodysplastic Syndrome |
5.0% |
| Weight Decreased |
4.2% |
| Vomiting |
4.0% |
| Somnolence |
3.8% |
| Varicella |
3.8% |
| Acute Myeloid Leukaemia |
3.7% |
| Pyrexia |
3.7% |
| Multiple Myeloma |
3.5% |
| White Blood Cell Count Decreased |
3.1% |
| Infection |
2.9% |
| Thrombosis |
2.9% |
| Deep Vein Thrombosis |
2.7% |
| Peripheral Sensory Neuropathy |
2.7% |
|
| Concomitant |
| Multiple Myeloma |
56.0% |
| Pain |
9.7% |
| Hypertension |
4.3% |
| Plasma Cell Myeloma |
4.2% |
| Product Used For Unknown Indication |
3.4% |
| Depression |
2.8% |
| Metastases To Bone |
2.2% |
| Neoplasm Malignant |
1.8% |
| Prophylaxis |
1.8% |
| Prostate Cancer |
1.7% |
| Anxiety |
1.7% |
| Anaemia |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Deep Vein Thrombosis |
1.2% |
| Osteoporosis |
1.2% |
| Plasmacytoma |
1.2% |
| Neuropathy Peripheral |
1.2% |
| Bone Disorder |
0.9% |
| Chemotherapy |
0.9% |
| Nuclear Magnetic Resonance Imaging |
0.9% |
|
| Weight Decreased |
16.5% |
| Tooth Extraction |
13.9% |
| Osteonecrosis |
11.1% |
| Wound Drainage |
9.5% |
| Vomiting |
7.8% |
| Vision Blurred |
5.9% |
| Weight Increased |
4.2% |
| Wheezing |
3.9% |
| Wound Debridement |
3.3% |
| Vertebroplasty |
3.0% |
| Pain In Jaw |
2.9% |
| Thrombocytopenia |
2.8% |
| Viral Infection |
2.1% |
| White Blood Cell Count Decreased |
2.1% |
| X-ray Abnormal |
2.1% |
| Upper Respiratory Tract Infection |
1.9% |
| Swelling |
1.8% |
| Multiple Myeloma |
1.7% |
| Urinary Tract Infection |
1.7% |
| Death |
1.6% |
|
| Interacting |
| Hypertension |
20.0% |
| Multiple Myeloma |
15.0% |
| Myelofibrosis |
15.0% |
| Parkinson's Disease |
15.0% |
| Systemic Lupus Erythematosus |
15.0% |
| Iron Overload |
10.0% |
| Hypocalcaemia |
5.0% |
| Hypokalaemia |
5.0% |
|
| Drug Interaction |
41.7% |
| Toxic Epidermal Necrolysis |
16.7% |
| Transaminases Increased |
16.7% |
| Splenomegaly |
8.3% |
| Syncope |
8.3% |
| Varicella |
8.3% |
|
